{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:24:59Z","timestamp":1791397499650,"version":"4.3.3"},"reference-count":5,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,3,28]]},"abstract":"<jats:p>This open-label randomized clinical trial assessed the 12-month risk of disease activity flares after discontinuation of conventional synthetic DMARDs (csDMARDs) compared with continuing half-dose csDMARDs in adult Norwegian patients with rheumatoid arthritis and excellent disease control.<\/jats:p>","DOI":"10.1001\/jama.2023.0492","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T15:01:13Z","timestamp":1680015673000},"page":"1024","source":"Crossref","is-referenced-by-count":5,"title":["Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Excellent Disease Control"],"prefix":"10.1001","volume":"329","author":[{"given":"Siri","family":"Lillegraven","sequence":"first","affiliation":[{"name":"Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Paulshus Sundlis\u00e6ter","sequence":"additional","affiliation":[{"name":"Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Birgitte","family":"Aga","sequence":"additional","affiliation":[{"name":"Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Sexton","sequence":"additional","affiliation":[{"name":"Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[{"name":"Leiden University Medical Centre, Department of Rheumatology, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen A.","family":"Haavardsholm","sequence":"additional","affiliation":[{"name":"Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"jld230006r1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"17","key":"jld230006r2","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1001\/jama.2021.4542","article-title":"Effect of half-dose vs stable-dose conventional synthetic disease-modifying antirheumatic drugs on disease flares in patients with rheumatoid arthritis in remission: the ARCTIC REWIND randomized clinical trial.","volume":"325","author":"Lillegraven","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"jld230006r3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1136\/annrheumdis-2014-206439","article-title":"Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy.","volume":"75","author":"Haschka","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"17","key":"jld230006r4","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1001\/jama.2021.2740","article-title":"Treatment strategies for patients with immune-mediated inflammatory diseases.","volume":"325","author":"Curtis","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"jld230006r5","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001220","article-title":"DMARD-free remission as novel treatment target in rheumatoid arthritis.","volume":"6","author":"Verstappen","year":"2020","journal-title":"RMD Open"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2802926\/jama_lillegraven_2023_ld_230006_1683208317.74533.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T01:55:41Z","timestamp":1683683741000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2802926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":5,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,3,28]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.0492","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,28]]}}}